|
Garlic in hyperlipidemia caused by HAART Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on Garlic in hyperlipidemia caused by HAART conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. Garlic in hyperlipidemia caused by HAART Clinical research trials and Garlic in hyperlipidemia caused by HAART health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like Garlic in hyperlipidemia caused by HAART. Garlic in hyperlipidemia caused by HAART Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Garlic in hyperlipidemia caused by HAART clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their Garlic in hyperlipidemia caused by HAART condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "G" Clinical Trials Conditions > Garlic in hyperlipidemia caused by HAART  Garlic in hyperlipidemia caused by HAART
Garlic in hyperlipidemia caused by HAART
For Condition: Hypercholesterolemia,Hyperglycemia,Hypertriglyceridemia,HIV Infections
Status: Terminated
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) ,
Synopsis: This is a double-blind randomized placebo controlled trial to test the use of garlic to lower cholesterol and triglycerides in hyperlipidemic HIV-infected individuals who are being treated with highly active antiretroviral therapy (HAART). The garlic will be administered as enteric-coated tablets and in two escalating dosages.
Details: Background: Clinical evaluation of garlic (Allium sativum L.) in HIV disease is warranted for several reasons. First, garlic is used as a botanical medicine and as an alternative therapy by many HIV-infected individuals. Baseline data from the Bastyr's Alternative Medicine Care Outcomes in AIDS (AMCOA) study [1] indicate that garlic is the most frequently used botanical medicine among HIV-infected men and women (52.9%) who utilize complementary and alternative medicine (CAM). In the same cohort, 50% of the subjects who use antiretroviral therapy are also taking garlic supplements. Second, there is a growing body of studies that indicate that garlic exhibits lipid and glucose lowering as well as hepato-protective activities. Third, several of the pharmacological activities of garlic and their reported clinical benefits in other conditions, especially in hyperlipidemia, may be relevant in the management of highly active antiretroviral therapy (HAART) in HIV-infected subjects. Study design: This is a phase II randomized double-blind, placebo controlled trial to study garlic as lipid lowering therapy in hyperlipidemic HIV-infected subjects treated with highly active antiretroviral therapy (HAART). Study Medication: We will utilize GarlicinTM, an allicin-standardized dried garlic supplement in two escalating doses (700 mg and 1400 mg /day) in HIV-infected subjects (n = 102, with 51/arm) who are receiving HAART. Study Aims: The primary aim of this study is to measure the effects of two escalating doses of GarlicinTM on total serum cholesterol. Secondary aims include determining the tolerability and adverse events associated with two escalating doses of GarlicinTM and gathering preliminary data on the effects on fasting serum triglycerides, glucose, insulin, transaminases (ALT and AST) and plasma HIV-1 RNA titers.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/65 Years
Genders: Both
Protocol Entry Criteria: HIV-1 seropositive confirmed by medical history. >18 years and < 65 years of age. On stable HAART for at least 6 months before study entry without the likelihood of HAART therapy changes in the following 6 months due to viral rebound or adverse events. CD4+ lymphocyte number > 100 cells/mm3 measured within 60 days before study entry. HIV-1 viral load < 2000 RNA copies/ml. Cholesterol > 200 mg/dL. Triglycerides > 250 mg/dL < 1000 mg/dL. Willing and able to avoid raw or dry garlic, onion, leeks and shallots as well as supplements containing garlic during the 16 weeks of the trial. Willing and able to provide inform consent. Willing and able to understand and follow protocol for the duration of the study. Willing and able to maintain a consistent lifestyle routine, eg. diet, exercise, medications, dietary supplements and sleep schedule for the duration of the study. Willing and able to understand and follow the Step 1 guidelines from the National Cholesterol Education Program (NCEP) for the duration of the study. Willing to remain adherent to the current HAART regimen.
Total Enrollment: 146
Location and Contact Information:
Overall Study Official:
LeannaStandish, Principal Investigator, Bastyr University
University of Washington Harborview Medical Center
Seattle, Washington, 98104
United States
Bastyr University Center for Natural Health
Seattle, Washington, 98103
United States
Additional Information:
Study ID Numbers: 1 R01 AT00328-01;
Study Start Date: November 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00029250
Other Hyperglycemia Studies:
1. A Study to Compare Three Doses of T-20 When Given in Combination with Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults
2. An Open-Label, Pilot Study to Evaluate the Development of Resistance to Nevirapine (BI-RG-587) in HIV-Infected Patients With CD4 Cell Count >= 500/mm3
3. Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
4. A Randomized Prospective Study of Pyrimethamine Therapy for Prevention of Toxoplasmic Encephalitis in HIV-Infected Individuals With Serologic Evidence of Latent Toxoplasma gondii Infection
5. Effects of home visits on medication adherence in children and youth with HIV
Related Studies:
Other Hyperglycemia Clinical Trials
Other Washington Clinical Trials
Other Seattle Clinical Trials
Garlic in hyperlipidemia caused by HAART
|
|
|
|
|
|
|
|
